Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer

Silexion Therapeutics Corp

BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.
Phase 2/3 trial initiation for SIL204 planned for Q2 2026, pending regulatory clearance.
Regulatory submissions expected in Israel by end of Q4 2025 and in Germany during Q1 2026.
SIL204 targets KRAS-driven locally advanced pancreatic cancer; momentum builds toward clinical launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.